Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology
What is your experience with directing treatment towards the androgen receptor in metastatic triple negative breast cancer?
Have you used anti-androgen therapy? Do you enroll patients on a trial or treat off label?
Answer from: Medical Oncologist at Academic Institution
There are increasing pre-clinical and clinical data of the potential role for targeting the androgen receptor (AR) in patients with metastatic triple negative breast cancer (TNBC) which express AR. Investigated agents include bicalutamide (Gulap et al CCR 2013) and abiraterone (Bonnefoi et a...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Targeting AR has a clinical benefit in appropriately selected patients with TNBC, but there are also a number of challenges in this space. For example, there is significant variability in the reported frequency (7% to 75%) and prognostic significance of AR expression in TNBC (Rampurwala et al. Clin ...